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INTRODUCTION
Acetylation and deacetylation of his-
tones help to regulate gene expression
with remodeling of chromatin, allowing
the binding of transcription factors. The
acetylation of histones is regulated by
two classes of enzymes: histone acetyl-
transferases and histone deacetylases
(HDACs) (1,2). Whereas the base pair se-
quence of DNA provides the fundamen-
tal code for proteins, posttranslational
modification of proteins plays a major
role in the control of gene transcription.
The amino acid tails of the core nucleoso-
mal histones are subject to posttransla-
tional modifications by acetylation of
lysines, methylation of lysines and
arginines, phosphorylation of serines and
ubiquitination of lysines. Because the key
acetylation takes place on lysine
residues, the term “lysine deacetylases”
(KDAC) can be used, particularly since
inhibitors of lysine deacetylases can hy-
peracetylate cytoplasmic proteins.
Butyrate is a naturally occurring in-
hibitor of HDACs that is thought to play
a role in the gastrointestinal tract. Bu-
tyrate compounds are also used to in-
crease hemoglobin levels in patients with
certain anemias due to genetic muta-
tions. Valproic acid is also an HDAC in-
hibitor and is used widely to treat
epilepsy and certain psychiatric prob-
lems. However, new synthetic HDAC in-
hibitors were developed primarily to
treat cancer, by modulating the expres-
sion of pro-apoptotic genes that have
been suppressed in malignant cells (2,3).
Orally active HDAC inhibitors appear
to lack organ toxicities and are well toler-
ated. Presently, HDAC inhibitors are
used to treat patients with advanced
solid and hematological tumors (3–5).
Suberoylanilide hydroxamic acid was ap-
proved for the treatment of cutaneous
T-cell lymphoma. In general, HDAC in-
hibition selectively alters the transcrip-
tion of few of the expressed genes (ap-
proximately 2% to 10% of expressed
genes are increased or decreased in their
rate of transcription) (6–9).
At concentrations lower than those
used for antitumor effects, HDAC in-
hibitors can modulate inflammation pri-
marily by reducing cytokine production
as well as immune responses (10–14).
Suberoylanilide hydroxamic acid can sup-
press acute graft versus host disease after
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allergenic bone marrow transplantation,
in part, by reducing proinflammatory cy-
tokine production (13,15). HDAC in-
hibitors have also been shown to reduce
the severity of disease in mouse models of
inflammatory bowel disease (16,17). In
other inflammatory and immune-
 mediated diseases such as models of
lupus (12,14,18), inhibitors of HDAC rep-
resent a new class of therapeutic options.
In the present study, we investigated the
HDAC inhibitor ITF2357 for safety and ef-
fects on ex vivo cytokine production in a
phase I trial of healthy  subjects.
MATERIALS AND METHODS
Human Subjects and Eligibility
The studies were approved by the Eth-
ical Commission of the Bavarian Physi-
cian’s Chamber (Munich, Germany). All
subjects provided written informed con-
sent in accordance with the Declaration
of Helsinki before enrollment. Subjects
were deemed healthy on the basis of a
clinical history, physical examination,
electrocardiogram (ECG) and laboratory
tests of blood and urine. Body weight
was between 60 and 95 kg and body
mass index was between 18 and 28 kg/
m2. Subjects were excluded because of
evidence of hepatitis B and C and HIV-1
infection. In addition, drug or alcohol
abuse, a donation of >400 mL blood dur-
ing the previous 3 mo and the use of pre-
scribed medication during the previous
30 d were exclusion criteria. Over-the-
counter medicine in the previous 14 d or
a history of severe allergic disease also
served as exclusion criteria. Subjects
were allowed to withdraw from the
study at any time. Subjects were hospi-
talized from 24 h before dosing until 48 h
after dosing and were followed for 7 d
after dosing. Table 1 summarizes the
subjects and the treatment schedules.
Study Design and Treatment Plan
The doses of ITF2357 were adminis-
tered as capsules in the morning after a
12-h fast. Placebo capsules were adminis-
tered in equal numbers. Three studies
were performed. The first was a single-
dose escalation study involving 40 sub-
jects treated with either a single dose of
50, 100, 200, 400 or 600 mg or placebo
(six actives and two placebos per group)
and 1 wk of follow-up. The second study
was a double-blind, randomized, pla-
cebo-controlled, multiple-dose study in
which 41 subjects received ITF2357 each
morning for 7 consecutive days at the
doses of 50, 100 and 200 mg once a day,
or 100 mg twice a day (eight actives and
two placebos per group; one subject did
not complete the study for personal rea-
sons). The subjects were treated for 1 wk,
with a follow-up period of 4 wks. The
third study was a single-dose open-label
crossover randomized food interaction
study where 24 subjects were treated
with 100 mg once a day in the fed and
fasted state and followed for 1 wk.
Pharmacokinetics
Pharmacokinetics was determined for
single or repeat doses of ITF2357. Venous
blood samples (5 mL) were collected into
heparinized tubes according to a prede-
termined schedule at the following time
points: 0, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 16,
24 and 48 h after dosing. After repeat
doses, blood samples were collected on
the first and the last day of treatment. In-
termediate blood sampling was done be-
fore each morning dose on day 1 to day 7
and 2 h after dosing on days 3 and 5 to
assess steady-state achievement. Plasma
concentrations of ITF2357 and its main
metabolites, ITF2374 and ITF2375, were
assayed using a specific and validated
liquid chromatography–tandem mass
spectrometry (LC-MS/MS) method. The
analyses were performed in two steps:
the first one for the determination of
ITF2357 and ITF2374 and the other for
the determination of ITF2375.
Plasma samples (250 μL), spiked with
the internal standards, were processed
by liquid–liquid extraction with diethyl
ether. After centrifugation, the organic
layer was separated and evaporated
under a nitrogen stream. The residue
was treated with 150 μL reconstitution
solvent (75% H2O/25% CH3CN, 0.1% tri-
fluoracetate [TFA]) and applied to the
LC-MS/MS system. The chromato-
graphic analysis was performed using an
end-capped Purospher STAR RP-18 col-
umn and mass spectrometry detection
with an API3000 (ABSciex) with a Turbo
Ion Spray source in positive mode. The
lower limit of quantitation for the three
compounds was 1 ng/mL. Pharmacoki-
netic parameters were calculated by non-
compartmental analysis.
Safety and Tolerability
A total of 105 subjects were enrolled:
64 subjects involved in single-dose stud-
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Table 1. Pharmacokinetics studies design and volunteers characteristics.
Number Age 
of range Duration of treatment 
Study design Treatment doses subjects (y) M/F (and follow-up)
Single rising oral doses, double-blind, 50, 100, 200, 400, 600 mg 40 21–39 M Single dose (1-wk follow-up)
placebo-controlled, randomized
Repeat rising oral doses, double blind, 50 mg every day, 100 mg every day, 41 21–40 M 7 d (4 wks follow-up)
placebo-controlled, randomized 200 mg every day, 100 mg twice a day
Single dose, food interaction study; 100 mg every day 24 25–39 M Single-dose crossover
open-label randomized
ies and 41 subjects in the repeated-dose
study (Table 1). ITF2357 was studied at
daily doses ranging from 50 to 600 mg in
single-dose study and 50 to 200 mg in re-
peat-dose study, with administration fre-
quencies of once or twice daily. All clini-
cal adverse events (AEs) and laboratory
abnormalities were evaluated by the in-
vestigators for a potential relationship to
ITF2357. Those considered possibly,
probably or definitely related to ITF2357
were classified as drug-related. Tolerabil-
ity was monitored throughout the study
periods and at follow-ups. Blood pres-
sure and heart rate were monitored be-
fore dosing and at the times of blood
sampling for pharmacokinetics. ECG was
recorded before, 24 and 48 h and 7 d
after dosing. Complete blood counts,
blood chemistries and urinalysis were
performed before and 12 h (only hema-
tology), 24 h, 48 h and 7 d after the last
dosing.
Ex Vivo Whole Blood Cultures for
Cytokine Production
Blood samples were drawn at various
times during the studies after oral dosing
to measure ex vivo unstimulated and
lipopolysaccharide (LPS)-induced cy-
tokine production. One mL of blood was
directly collected in sterile heparinized
culture tubes containing a premeasured
(1 mL) amount of RPMI 1640 (Cellgro
Mediatech, Manassas, VA, USA) tissue
culture fluid or 1 mL RPMI 1640 contain-
ing 20 ng LPS (Escherichia coli serotype
0127: B8; Sigma, St. Louis, MO, USA).
Therefore, the final concentration of LPS
was 10 ng/mL, since the blood was di-
luted one part in two. After 2, 4, 8, 12
and 24 h at 37°C, the supernatant was re-
moved and frozen at –80°C until assayed
for cytokines. The white blood cell
(WBC) counts and the monocyte and
lymphocyte counts were obtained for
each experimental condition. The relative
concentrations of cytokines were calcu-
lated per million cells. Mature IL-1β,
tumor necrosis factor (TNF)-α, inter-
leukin (IL)-6, IL-10, IL-1Ra and interferon
(IFN)-γ were assayed by the electro-
chemiluminescence (ECL) method
(BioVeris, Gaithersburg, MD, USA). Anti-
bodies for these assays were purchased
(R&D Systems, Minneapolis, MN, USA)
and biotinylated and ruthenylated ac-
cording to the manufacturer’s instruc-
tions (BioVeris). The cytokine standards
were obtained from Peprotech (Rocky
Hill, NJ, USA). The lowest limit of detec-
tion of the ECL assay was 20 pg/mL for
each cytokine.
RESULTS
Safety and Tolerability of ITF2357
A total of 104 subjects gave informed
consent. In the single-dose study, nine
moderate adverse effects (AEs) were re-
ported by six (15%) subjects, but these
occurred only in the groups treated with
≥200 mg. Seven of the nine moderate
AEs were judged as possibly related to
the study drug by the investigators. The
most frequently reported AE was
headache (n = 4) of mild-to-moderate
severity.
In the repeat-dose study, there were 40
AEs. AEs were classified as mild (31/40,
77%) or moderate (9/40, 22%). No AEs
were classified as severe. AEs were re-
ported by 12 (29%) subjects out of 41
treated: 10 subjects treated with ITF2357
and 2 with placebo. No AEs were reported
by subjects receiving 50 or 100 mg ITF2357.
The most frequently reported AEs were
headache (n = 6 by four subjects), palpita-
tions (n = 8 by two subjects), dysuria (n = 5
by one subject), nausea (n = 2 by two sub-
jects with one in placebo) and abdominal
pain (n = 3 by two subjects with one in pla-
cebo). A total of 26 AEs (26/40, 65%) were
assessed as possibly related to the study
drug by the investigators.
Hematologic Changes
Nonspecific changes in WBC counts
were observed at doses up to 200 mg/
day. A reduction in platelet counts was
observed across all ITF2357-treated
groups. The magnitude of the decrease
was dose dependent. The effect was evi-
dent from day 5 onward, reaching the
lowest value on day 9, that is, 48 h after
last dosing. On day 9, the mean platelet
counts decreased by 17%, 25% and 35%
in groups receiving 50, 100 and 200 mg
ITF2357 each day, respectively (Figure 1).
For the most part, the effect on platelets
recovered on day 14 (7 d after last dos-
ing) and was fully reversed 4 wks after
the last dosing (see Figure 1). The pattern
of platelet decrease in the group receiv-
ing 100 mg ITF2357 twice a day was
comparable to that observed in the group
receiving 200 mg each day. Additional
hematological evaluation performed in
the 100-mg twice-a-day group revealed
that the effect was more pronounced on
day 11; the trend reversed toward nor-
mality on day 14 and full recovery was
observed on day 21 onwards.
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Figure 1. Platelet counts in healthy volunteers receiving 7-day oral doses of ITF2357 or pla-
cebo. Mean platelet counts in ITF2357-treated group receiving 50, 100 and 200 mg
ITF2357 each day, respectively, are shown.
Routine Laboratory Findings
There were no changes in liver or renal
function tests at any dose or dosing
schedule, using standard hospital clinical
laboratory–based methods.
Pharmacokinetics of Single Oral Dose
ITF2357
The mean plasma concentrations of
ITF2357 after single oral administration
are shown in Figure 2. They reached
peak levels approximately 2 h after dos-
ing for all dose levels and displayed
biphasic elimination profiles with a mean
apparent terminal elimination phase
(half-life) ranging from 5.3 to 6.9 h. Dose-
proportionality of the drug was assessed
over the 50- to 600-mg dose range. A pro-
portional increase in area under the
curve (AUC) and Cmax of the drug with
increasing dose levels of ITF2357 was ob-
served (Table 2).
Repeated Oral Doses
Doses of 50, 100 and 200 mg once a
day and 100 mg twice a day were consid-
ered safe on the basis of toxicokinetic
studies in various animal species and the
single-dose study in volunteers. There-
fore, a 7-d repeat-dose study in healthy
volunteers was performed. In the once-a-
day treatments, maximal concentration
of the drug was reached within 2.1–2.6 h
of administration. A slightly longer but
statistically not significantly different tmax
was observed with the twice-a-day treat-
ment (Table 3 and Figure 3). The peak
levels (Cmax) of the 100-mg ITF2357
twice-a-day regimen observed on day 7
are statistically different (P < 0.05) from
those seen on day 1, whereas there was
no statistical difference at the other dose
regimens. The apparent elimination half-
life of ITF2357 was fairly comparable be-
tween the 50-, 100- and 200-mg doses,
ranging between 5.73 and 6.15 h on day
1 and 6.47 and 7.31 h on day 7. On the
basis of the above data and the predose
concentration values of ITF2357 (not
shown), steady state was achieved
within 5–7 d for the single-dose regi-
mens. In contrast, steady state for the
twice-a-day dose was reached after 7 d
from the first treatment.
ITF2357 gives two main metabolites in
vivo deriving from the biotransformation
of the hydroxamate moiety into a car-
boxylate (ITF2375) or into an amide
group (ITF2374). The metabolites inhibit
HDAC enzymes at concentrations in the
high micromolar–low millimolar
range—therefore, 3 to 5 orders of magni-
tude larger than the effect of ITF2357 on
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Table 3. Pharmacokinetics parameters after a repeat (7-day) rising dose in healthy volunteers.
50 mg every day 100 mg every day 200 mg every day 100 mg twice a day
Dose Day 1 Day 7 Day 1 Day 7 Day 1 Day 7 Day 1a Day 7a
Cmax (ng/mL) 56 ± 5 67 ± 5 124 ± 9 135 ± 10 322 ± 26 283 ± 16 116 ± 15 182
b ± 17
Cmin (ng/mL) 2.4 ± 0.2 3.5 ± 0.2 4.1 ± 0.3 5.5 ± 0.3 10.2 ± 1.3 12.0 ± 1.4 17.7 ± 1.6 30.9 ± 2.6
tmax (h) 2.5 ± 0.5 2.1 ± 0.4 2.6 ± 0.4 2.8 ± 0.34 2.4 ± 0.4 2.6 ± 0.4 2.8 ± 0.4 3.1 ± 0.6
AUC0-t (ng · h/mL) 369 ± 23 452 ± 20 771 ± 27 891 ± 32 1875 ± 102 1,907 ± 130 1,326 ± 148 1,084 ± 84
Half-life (h) — 7.31 ± 0.16 — 6.47 ± 0.22 — 6.54 ± 0.16 — —
aFirst daily dose.
bStatistically significant difference (P < 0.05) from day 1 Cmax.
Figure 2. Pharmacokinetics of ITF2357 in healthy male subjects after administration of a single
oral dose. Mean (± SD) plasma concentrations of ITF2357 are shown. n = 9 in each group.
Table 2. Pharmacokinetics parameters after single rising dose to healthy volunteers.
Dose 50 mg 100 mg 200 mg 400 mg 600 mg
Cmax ng/mL 53 ± 5 99 ± 13 236 ± 25 526.3 ± 67.3 542 ± 93
nmol/L 111 ± 10 207 ± 28 495 ± 53 1,106 ± 141 1,139 ± 195
tmax (h) 2.0 ± 0.44 2.09 ± 0.45 2.17 ± 0.40 2.17 ± 0.40 3.67 ± 0.61
AUC ng · h/mL 359 ± 26 671 ± 36 1,346 ± 158 2,503 ± 312 3,543 ± 486
nmol/L · h 754 ± 55 1,410 ± 76 2,828 ± 332 5,259 ± 656 7,444 ± 1,021
Half-life (h) 6.9 ± 0.43 6.0 ± 0.15 6.0 ± 0.40 5.7 ± 0.32 5.3 ± 0.32
CL/Fa (L/min) 2.38 ± 0.17 2.52 ± 0.14 2.64 ± 0.28 2.96 ± 0.49 3.15 ± 0.51
aClearance fluid compartment.
these enzymes. In preclinical models,
they do not contribute to the efficacy of
active doses of ITF2357. These two
metabolites were seen in both the single-
and repeat-dose studies. ITF2375 was
the more abundant one, with its meta-
bolic ratio to the parent compound being
approximately 4. Peak plasma concen-
trations of ITF2375 were observed 3 to
5 h after administration. The appearance
of ITF2374 was delayed, with its concen-
trations peaking between 6.7 and 8 h.
The metabolic ratio of ITF2374 to
ITF2357 was <1. The AUC at 0 time
(AUC0-t) and Cmax of ITF2357 and
ITF2375 increased proportionally with
the dose, whereas the increase of ITF2374
was more than  proportional.
Cytokine Production in Ex Vivo Whole
Blood Cultures
Whole heparinized blood taken at
 various time points after oral dosing
was cultured for 24 h with endotoxin
(10 ng/ mL), and the supernatants were
assayed for IL-1β, TNFα, IL-6, IL-1Ra,
IL-10 and IFNγ. As shown in Figure 4A,
the maximal decrease in TNFα produc-
tion occurred at 4 h at all doses, and the
4-h time point was also the time of maxi-
mal decrease in IL-1β (Figure 4B). At a
dose of 100 mg, the mean maximal con-
centration of ITF2357 of approximately
100 ng/mL (200 nmol/L) occurs at 2 h.
However, the mean decrease in TNFα of
about 37% (P = NS) of baseline occurs at
4 h. After an oral dose of 50 mg, the
 maximal concentration at 2 h is about
100 nmol/L. At 4 h after dosing, the
mean reduction in LPS-induced TNFα
was 51% (P = 0.02). The concentration of
ITF2357 carried over in the plasma of the
subjects into the culture is slightly lower
(see Figure 2); however, since the blood
is diluted in the whole blood culture one
part in two, the concentration is 50%
lower. For example, using a single dose
of 50 mg, the concentration of ITF2357 at
4 h is approximately 40 nmol/L and the
concentration carried over into the cul-
ture would be 20 nmol/L. At 20 nmol/L,
LPS-induced cytokines in peripheral
blood mononuclear cells (PBMCs) is sig-
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Figure 3. Pharmacokinetics of ITF2357 in healthy male subjects during seven daily doses.
(A) Mean (± SD) plasma concentrations of ITF2357 after the first single oral dose are
shown. (B) Mean (± SD) plasma ITF2357 on day 7 after seven daily doses. n = 8 in each
group.
Figure 4. LPS-induced TNFα and IL-1β in whole blood cultures. The percent change in cy-
tokine levels shown on the y axis are derived from 24-h cultures of whole blood obtained
at each time point shown under the horizontal axis. (A) Mean ± SEM percent change of
TNFs per mL from basal production (mean for group 815 ± 205 pg/mL) just before a single
oral dose. (B) IL-1β in the same samples shown in A. Mean ± SEM basal IL-1β for the group
was 1,020 ± 525 pg/mL. n = 9 for each group.
nificantly reduced (19). A similar reduc-
tion in IL-1β was also observed (see Fig-
ure 4B), particularly at the 100-mg dose
(–77%, P = 0.001).
By 12 and 24 h after a single dose of
ITF2357, there is no significant reduction
of either TNFα or IL-1β in whole blood
cultures from subjects treated with 50 or
100 mg, although in the 200- and 400-mg
dose group, reductions at 12 h but not
24 h were observed. We next examined
the production of TNFα and IL-1β at 12
and 24 h, calculating the cytokines per
million WBCs. As shown in Figure 5A
and B, there is no suppression at 12 and
24 h when the amount of cytokine is ex-
amined per million WBCs in the 50- and
100-mg dose group, although suppres-
sion was present in the 200- and 400-mg
group. By 24 h, all dosing groups pro-
duced cytokines comparable to that of
the baseline level. From these data, we
conclude that the ITF2357-associated re-
duction of LPS-induced TNFα and IL-1β
production in whole blood cultures is
transient and returns to predrug levels
by 12 h after dosing.
Effect of Seven Daily Doses of ITF2357
on Cytokine Production
A daily dosing regimen was carried
out to ascertain whether a sustained
course of ITF2357 would affect cytokine
production different from that observed
after a single dose (Figure 6A, B). As
shown in Figure 6B, the reduction in
IL-1β after seven daily doses of 200 mg is
nearly the same as that observed after
the first day. Nearly the same pattern as
shown in Figure 6 was observed on day 7
for TNFα, IL-6 and IFNγ (data not
shown).
IL-6 and IFNγ Production
In the same samples of data shown in
Figure 4, we measured levels of IL-6 and
IFNγ induced by LPS. These data are
shown in Figure 7A and B. A single dose
of 50 mg resulted in a statistically signifi-
cant (P = 0.01) reduction in IFNγ of 63%
compared with that of the placebo group
at the 4-h time point (see Figure 7B). The
reduction was 77% at a dose of 100 mg.
IL-6 was also reduced at the 4-h time
point (–45%, P = 0.05). However, 12 h
after dosing, production of IFNγ returns
and exceeds that of basal levels (not sig-
nificant). A similar pattern was observed
for IL-6 (see Figure 7A).
The amount of IFNγ was also calcu-
lated per million lymphocytes, since in
the LPS model used in the present study,
LPS induces IL-12 and IL-18, which in
turn, induce T-cells to produce IFNγ. As
shown in Figure 8, the production of
IFNγ at 12 and 24 h based on per million
lymphocytes is no different from that
observed per million WBCs, except that
the elevated production 12 h (Figure 9B)
after 50 or 100 mg is no longer observed
per million lymphocytes (see Figure 8).
No Decrease in IL-1Ra
As shown in Figure 10, there were no
significant decreases at 4 h at all doses,
including the placebo. Of note, at the
50-mg dose, there was an increased pro-
duction of IL-1Ra at 4 h, and it was sus-
tained after 8 h before returning to base-
line levels after 24 h; however, these
levels were not statistically significant.
These samples in which IL-1Ra was de-
termined are the same as those used to
measure changes in TNFα and IL-1β pro-
duction (see Figure 4A, B). There were
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Figure 5. Production of LPS-induced TNFα
and IL-1β per WBC. (A) Mean ± SEM of
TNFα expressed as percent change from
baseline. The percent change in cytokine
levels shown on the y axis are derived
from 24-h cultures of whole blood ob-
tained at 12- and 24-h time points. (B) IL-1β
in the same samples shown in A. n = 9 in
each group.
Figure 6. Comparison of a single dose day 1 and day 7 of ITF2357 on LPS-induced IL-1β.
The percent change in cytokine levels shown on the y axis are derived from 24-h cultures
of whole blood obtained at each time point shown under the horizontal axis. (A) Mean ±
SEM of IL-1β per mL expressed as percent change of basal production (980 ± 325 pg/mL)
just before the single oral administration. (B) Mean ± SEM on day 7 of IL-1β after the 7th
daily dose of 200 mg. Basal production was 1,144 ± 625 pg/mL. n = 9 for each group.
no statistically significant changes in
IL-10 production at doses of 50 or
100 mg each day (data not shown).
Effect of ITF2357 on Platelet Counts
Subjects were treated with daily dos-
ing for 7 d and platelet counts were de-
termined. A reduction in platelet counts
was observed across all ITF2357-treated
groups. As shown in Figure 1, the magni-
tude of the decrease was clearly dose de-
pendent. The effect was evident from
day 5 onward, reaching the lowest value
on day 9 (that is, 48 h after the last dos-
ing). On day 9, the mean platelet counts
decreased by 17, 25 and 35% in groups
receiving 50, 100 and 200 mg ITF2357
each day, respectively (see Figure 1). For
the most part, the effect on platelets re-
covered on day 14 (7 d after the last dos-
ing) and was fully reversed 4 wks after
the last dosing (see Figure 1). The pattern
of platelet decrease in the group receiv-
ing 100 mg ITF2357 twice a day was
comparable to that observed in the group
receiving 200 mg each day. Additional
hematological evaluation performed in
the 100 mg twice a day group revealed
that the effect was more pronounced on
day 11; the trend reversed toward nor-
mality on day 14, and full recovery was
observed on day 21 onwards.
DISCUSSION
These studies described the first evalu-
ation of the pharmacokinetics, safety and
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Figure 7. LPS-induced IL-6 and IFNγ in whole blood cultures. The percent change in cytokine
levels shown on the y axis are derived from 24-h cultures of whole blood obtained at each
time point shown under the horizontal axis. (A) Mean ± SEM percent change of IL-6 per mL
from basal production (860 ± 356 pg/mL) just before a single oral dose. (B) IFNγ in the same
samples shown in A. Mean ± SEM basal IFNγ was 485 ± 137 pg/mL. n = 9 for each group.
Figure 8. LPS-induced IL-6 and IFNγ per
WBC. (A) Mean ± SEM of IL-6 per million
WBC expressed as percent change of
basal production just before the oral dos-
ing. The hours after the dose are indicated
under the horizontal axis. (B) IFNγ in the
same sample shown in A. n = 9 for each
group.
Figure 9. Production of LPS-induced IFNγ
per lymphocyte. Mean ± SEM of IFNγ ex-
pressed as percent change from baseline
per million lymphocytes 12 and 24 h after
a single dose. n = 9 in each group.
tolerability of the oral histone deacety-
lase inhibitor ITF2357 (givinostat) in hu-
mans after the administration of increas-
ing single and multiple doses. Similar to
the short-term use, there were no serious
adverse effects of ITF2357 in the long-
term studies (data not shown). In addi-
tion, food intake did not affect the phar-
macokinetics of ITF2357 (data not
shown). ITF2357 was found to be orally
available, eliminated slowly and dis-
played dose-proportional pharmacoki-
netics up to a total dose of 600 mg/day.
No further increases in concentrations in
plasma were observed with the multiple
doses after 7 days, suggesting that there
was no accumulation of the drug. This
result was confirmed by the ratio of the
AUC on day 7 to the AUC on day 1,
which was close to unity in all cases
(Table 3). After the administration of all
dose levels in both studies, ITF2357 was
quickly metabolized with a half-life rang-
ing from approximately 5 to 7 hours, de-
pending on the dose regimen. This result
implies that twice-daily dosing would be
an appropriate clinical dosage regimen
for treating inflammatory conditions. In
fact, twice-daily dosing was used to treat
children with systemic-onset juvenile ido-
pathic arthritis with ITF2357 for 12 weeks
at a 1.5 mg/kg total daily dose (20).
The results from these studies of the
pharmacokinetics of ITF2357 in humans
corroborate findings from preclinical in-
vestigations with animals, in which dose-
related increases in exposure were ob-
served in others species. In rats, dogs,
rabbits and monkeys, the drug is elimi-
nated by biotransformation and the
metabolites are produced by several en-
zymes and are eliminated by biliary and
renal excretion; only traces of unchanged
ITF2357 were found in urine. In repeat
oral toxicity studies in rats, the drug was
administered consecutively up to
26 weeks. A dose of 50 mg/kg/day ad-
ministered for 4 consecutive weeks was
determined to be safe. In other two stud-
ies (of 13 and 26 weeks), there was no
adverse effect level of the drug at 
10 mg/ kg/day. The data in the 36-week
study in monkeys showed no adverse ef-
fects at the dose of 12 mg/kg/day.
In humans, ITF2357 was well tolerated
in both the single-dose and multiple-
dose trials. The most commonly reported
AEs were mild to moderate and nonspe-
cific and included headache, nausea, pal-
pitations and dysuria. There also was no
suggestion that ITF2357 caused cardiac
AEs, including clinically significant ECG
findings or QT prolongation. There were
clearly reduced platelets in subjects re-
ceiving the higher doses of ITF2357. Inhi-
bition of histone deacetylase enzymes
and reducing synthesis and release of
several cytokines can explain the effect
on platelet reduction. Thrombocytopenia
is also reported for other HDAC in-
hibitors. The platelet count never
dropped to critical values, even with
higher doses, and consistently showed a
rapid recovery after the discontinuation
of the drug.
Safety is always a fundamental consid-
eration when evaluating a drug, particu-
larly when used in the treatment of dis-
eases with no immediate danger to the
patient. Although the single doses of 200
and 600 mg resulted in a marked de-
crease in cytokines, these doses were also
associated with a greater lowering of
platelets as well as gastrointestinal side
effects. Therefore, the likely therapeutic
dosing will be 50 or 100 mg/day in twice
divided doses. A dose of 1.5 mg/kg di-
vided in two doses was used to treat
children with systemic-onset juvenile id-
iopathic arthritis. In that study, ITF2357
was safe and effective after 12 weeks of
therapy (21). The equivalent dose in
adult humans is approximately 100 mg
total per day.
These studies also established that
ITF2357 is an antiinflammatory agent in
ex vivo cultures of whole blood. The pres-
ent work expands the finding that
HDAC inhibition reduces cytokine pro-
duction from PBMCs in vitro, particularly
cytokines relevant to autoimmune/ 
inflammatory diseases. The implications
of these studies are that inhibition of
HDAC by low oral doses of ITF2357 may
be effective in the treatment of certain
autoimmune and autoinflammatory dis-
eases, particularly those currently treated
with TNFα or IL-1β blockade. Inhibitors
of HDAC increase as well as decrease an
equal number of genes in the same cells
(22). Although the general property of in-
hibitors of HDAC is one of increasing
gene expression of proapoptotic genes in
cancer cells (23), this property requires
micromolar concentrations in vitro and
comparable concentrations in vivo. At
nanomolar concentrations, ITF2357 sup-
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Figure 10. LPS-induced IL-1Ra in while blood cultures. Mean ± SEM of IL-1Ra per mL ex-
pressed as percent change of basal production (1,212 ± 102 pg/mL) just before a single
oral dose. The hours after the dose are indicated under the horizontal axis. The percent
change in cytokine levels shown on the y axis are derived from the 24-h cultures of whole
blood obtained at each time point shown under the horizontal axis. n = 9 for each group.
presses cytokines in LPS-stimulated
PBMCs (19). Indeed, the concentrations
of ITF2357, which are carried over into
the whole blood cultures, were in the
low nanomolar range, particularly at the
dose of 100 mg at the 4-hour time point.
The precise mechanisms of cytokine
inhibition by ITF2357 remain unclear.
The acetylation state of the subunit p65
plays a critical role in the regulation of
nuclear factor (NF)-κB (24). Such studies
may explain the anti-cytokine effect of
ITF2357, especially on TNFα production
(19). Thus, an inhibition of NFκB-
 dependent transcription by the HDAC
inhibitors could possibly contribute to
suppression of inflammation. Whatever
the mechanism of ITF2357 suppression of
LPS-induced cytokines in the whole
blood culture, the maximal reduction
was consistently observed 4 hours after
the 50- and 100-mg doses, not 2 hours
after dosing (this latter time point being
the maximal plasma concentration).
These data suggest that the circulating
cytokine-producing cells have been af-
fected by exposure to ITF2357 in vivo and
exhibit a reduced ability to produce LPS-
induced cytokine hours later. Thus, the
data do not support the concept that the
suppression was due to the carryover of
ITF2357 into the culture; rather, suppres-
sion appears to be via a mechanism that
required at least 2 hours after maximal
exposure to ITF2357.
The reduction in secretion of LPS-
 induced IL-1β is not inconsequential
from a clinical perspective. Indeed, se-
vere systemic inflammatory diseases are
due to greater release of active IL-1β
from cultured PBMCs in vitro compared
with PBMCs from healthy subjects.
These diseases include systemic-onset
juvenile idiopathic arthritis (25), Muckle-
Wells syndrome (26,27), familial cold-
 induced autoinflammatory syndrome
(28), neonatal-onset multisystem inflam-
matory disease (29), hyper IgD syn-
drome (30) and Schnitzler’s syndrome
(31). The increased secretion of IL-1β in
these diseases is due to a single-point
mutation in the NOD-like receptor family
pryin domain containing 3 (NLRP3) gene,
which controls the activation of procas-
pase-1 (27,32). Alternatively, ITF2357
may affect the ability to secrete IL-1β via
the specialized secretory lysosomal path-
way and activation of phosphatidyl-
choline- specific phospholipase C (33).
Another pathway in the secretion of 
IL-1β is the P2X7 receptor (34,35), which
may also be affected by mechanisms of
 hyperacetylation.
Secretion of active IL-1β appears to be
the likely mechanism by which there is
a reduction in IL-1β activity. In the
Leoni studies with suberoylanilide hy-
droxamic acid (10) as well as ITF2357
(19), there was no decrease in steady-
state mRNA coding for IL-1β and no de-
crease in the amount of the IL-1β pre-
cursor. Thus, the likely mechanism for
reduced IL-1β activity appears to be at
the posttranslational level and specifi-
cally at processing the precursor to the
active mature form. However, we have
no evidence that ITF2357 inhibits cas-
pase-1 activity. In a study by Carta et al.
(36), suberoylanilide hydroxamic acid or
ITF2357 prevented the exocytosis of IL-
1β-containing secretory lysosomes. At
nanomolar concentrations, ITF2357 re-
duced the secretion of IL-1β after ATP
activation of the P2X7 receptor. Whereas
the inhibition of HDACs results in hy-
peracetylation of tubulin, acetylation of
HSP90 was unaffected. The reduction in
IL-1β secretion appears to be due to dis-
ruption of microtubules impairing lyso-
some exocytosis (36).
Although this study was a phase I trial
on the safety and tolerability of ITF2357,
the pharmacokinetic data are helpful in
future trials, particularly concerning the
twice-daily dosing schedules. The tran-
sient reduction in inducible cytokines at
50 and 100 mg in whole blood cultures
can be viewed as both a mechanism of
action at clinically achievable doses as
well as a safety margin. Cytokine block-
ade such as the widespread use of anti-
TNFα monoclonal antibodies are associ-
ated with increased opportunistic
infections and possibly lymphoma. There
appears to be a greater incidence of in-
fections associated with long-lasting
monoclonal antibodies such as infliximab
and adalimumab compared with etaner-
cept (37). One explanation for these dif-
ferences affecting host responses to infec-
tion is the differences in half-lives of
these agents. Infliximab has the longest
duration in the circulation (weeks),
whereas etanercept has the shortest
(days). Therefore, the short duration of
cytokine inhibition by ITF2357 may pro-
vide a greater parameter of safety com-
pared with long-acting cytokine
 inhibitors.
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